Improvement of glucose tolerance in hypertensive diabetic patients treated with guanfacine one year.
In the present study the effect of 1 year of antihypertensive treatment with guanfacine (g) has been evaluated in 18 hypertensive patients with adult-onset, non-insulin-dependent diabetes mellitus (WHO Type II). The treatment produced a marked improvement in the oral glucose tolerance test; guanfacine significantly decreased serum glucose levels, and affected only slightly the insulin secretion. It is suggested that the effect of g may be mediated via a reduction in catecholamine and/or growth hormone and ACTH secretion. The present results also suggest that treatment with guanfacine may improve individual coronary risk in hypertensive diabetic patients.
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D005951:Glucose Tolerance Test; D016316:Guanfacine; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000627:therapeutic use*; D011446:Prospective Studies; D013997:Time Factors
D000959:Antihypertensive Agents; D001786:Blood Glucose; D006146:Guanidines; D007328:Insulin; D010648:Phenylacetates; D016316:Guanfacine